In this context, high-sensitivity (hs) assays for CRP have been developed that provide both diagnostic and prognostic information. 14, 15, 17 Studies have shown that hs assays detect CRP concentrations with the required precision even in patients Rationale: Inflammation in the setting of acute myocardial infarction (MI) has been linked to risk stratification; however, the release kinetics of inflammatory biomarkers in patients with acute MI has been difficult to establish.
C ardiovascular disease, including acute myocardial infarction (AMI), is the leading cause of death in Western countries. 1 Proinflammatory cytokines like interleukin-6 (IL-6) and acute-phase proteins such as C-reactive protein (CRP) are upregulated in patients with AMI. 2, 3 Studies have suggested that using data on levels of biomarkers such as soluble CD40 ligand (sCD40L) in combination with cardiac troponins might helpful in the diagnosis of patients with acute coronary syndromes. [4] [5] [6] Several studies have also reported that inflammation is associated with long-term outcome in patients with acute coronary syndrome. [7] [8] [9] IL-6 has an effect on cardiac function, acting through various mechanisms including the induction of cardiomyocyte apoptosis. 10 In addition, IL-6 concentrations are affected by circadian rhythm and physical exercise. 11, 12 Furthermore, data are emerging that support an association between CRP elevation and culprit lesion plaque rupture in acute coronary syndrome, [13] [14] [15] which is triggered by inflammatory responses and plaque degradation.
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with stable coronary artery disease. 18 Hs-CRP is known to be an independent predictor of recurrent events, including myocardial infarction (MI), restenosis after percutaneous coronary intervention, and death. 17, 18 However, thus far there have been no studies published that have addressed the differences in inflammation kinetics in patients with AMI. Several animal studies provided information about the release kinetics of inflammatory biomarkers during the course of AMI 9, 19 ; however, these findings cannot be directly extrapolated to patients because of different physiological parameters (eg, metabolism, release, interindividual variability) or proinflammatory effects of surgical procedures performed to induce myocardial infarction. [20] [21] [22] [23] Because of the imprecise definition of the exact time point of the beginning of myocardial ischemia and the patient-related delay before presentation to the hospital, the early release kinetics of hs-CRP and, IL-6, and sCD40L as well as the initial kinetics of circulating leukocyte subsets after human AMI are entirely unknown. Therefore, the objective of the present study was to characterize the time course of inflammatory biomarkers and early shifts of circulating myeloid cell subsets in patients undergoing transcoronary ablation of septal hypertrophy (TASH) as a model for patients with AMI.
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Methods
Study Design
From January 2010 to June 2011, 21 consecutive patients with hypertrophic obstructive cardiomyopathy undergoing TASH were included in the study. Pre-and postprocedural management of the patients has been published recently. 24, 25 In brief, clinical history, physical examination, 12-lead ECG, laboratory tests, echocardiography, and coronary angiography for all patients were assessed. The final diagnosis of hypertrophic obstructive cardiomyopathy was made according to the current guidelines based on severe symptoms during physical activity, asymmetrical septal hypertrophy >15 mm, systolic movement of the anterior mitral valve leaflet, and an intraventricular pressure gradient of 30 mm Hg at rest and >50 mm Hg after provocation by the Valsalva maneuver. 26 All patients received analgesic and anxiolytic pretreatment. None of the patients showed clinical signs of infectious diseases or liver insufficiency. TASH was performed according to standard clinical practice with temporary septal branch occlusion for selective therapeutic injection of 96% ethanol. Postprocedural management included monitoring in the intensive care unit for 48 hours. All patients provided written informed consent for their participation in the study, and approval of the ethics board (FF 31/2010) was obtained. Twenty patients without any evidence of coronary artery disease or inflammatory disorder undergoing coronary angiography without percutaneous coronary intervention served as the control group. All patients from the control group provided written informed consent for their participation in the study, and approval of the local ethics board (FF 43/2010) was obtained. The investigation conforms to the principles outlined in the Declaration of Helsinki.
Blood Sample Collection and Processing
Venous blood samples for determination of CRP, IL-6, and sCD40L were collected in plain gel-filled tubes without additives and in EDTA-filled tubes (Sarstedt, Germany) before treatment and at 15, 30, 45, 60, 75, 90 , and 105 minutes and at 2, 4, 8, and 24 hours after induction of myocardial infarction. In the control group, venous blood samples for determination of CRP and IL-6 were collected in gel-filled tubes without additives and in EDTA-filled tubes before and at 2, 4, and 24 hours after coronary angiography. Sera were processed immediately and frozen at -80°C until assay.
CRP and Interleukin Measurements
CRP was measured in serum with the high-sensitivity electrochemiluminescence immunoassay (hs-CRP assay; Elecsys Analyzer 2010, Roche Diagnostics, Mannheim, Germany). The lower detection limit for the hs-CRP assay is 0.15 mg/L and the highest concentration measurable is 20.0 mg/L. The lowest concentration measurable with a coefficient of variation <10% for this assay is 0.3 mg/L. CRP was also measured using a commercial 1-step electrochemiluminescence immunoassay (CRP assay third generation; Elecsys 2010, Roche Diagnostics, Mannheim, Germany). The lower detection limit of this assay is 0.3 mg/dL and the highest concentration measurable is 350.0 mg/dL. The lowest concentration measurable with a coefficient of variation <20% is 0.6 mg/dL.
IL-6 was measured in serum using a chemiluminescent microparticle immunoassay (IL-6 assay; Elecsys Analyzer 2010, Roche Diagnostics, Mannheim, Germany). The lower detection limit of this assay is 1.5 pg/mL, the 95th percentile is 7.0 pg/mL, and the lowest concentration measurable with a coefficient of variation < 10% is 5.0 pg/mL.
The sCD40L concentration was measured in plasma using a quantitative sandwich immunoassay (human sCD40L assay; Quantikine, R&D Systems, Inc, MN). According to the manufacturer, the mean minimum detectable concentration of CD40 ligand is 4.2 pg/mL.
Determination of Peripheral Blood Leukocyte Subsets
Absolute counts of peripheral blood granulocyte and monocyte subpopulations were determined using BD TruCount flow cytometry assay (Cat. No. 340334, BD Biosciences). Briefly, 50 μL of freshly drawn peripheral EDTA-treated blood was added into TruCount tubes using reverse pipetting and was then stained with mixed antibody conjugates, including anti-CD14-AlexaFluor488, anti-CD66b-PerCpCy5-5, anti-CD16-APC (BD Biosciences), and anti-CD11b-AlexaFluor700 (BD) monoclonal antibodies. After a 20-minute incubation at room temperature in the dark, erythrocytes were lysed for 15 minutes with 1000 μL ammonium chloride-based lysis buffer (BD PharmLyse, Cat. No. 555899, BD Biosciences). Data acquisition was performed on BD FACS Verse flow cytometer using FACSSuite software (BD Biosciences). A defined number (10 000) of CD66b-positive granulocytes were counted for the stop gate. Spectral overlap between different channels was calculated automatically by the FACSDiva software after measuring single-color compensation controls. Optimal compensation was achieved using antibody capture beads (Anti-Mouse Ig, κ CompBeads, Cat. No. 552843 BD Biosciences) and the corresponding conjugated antibodies. Data were analyzed using FACS-Diva Software and absolute cell counts per microliter peripheral blood were calculated according to the manufacturer's protocol.
Statistical Analysis
All data for continuous variables are expressed as mean±SD or as median and interquartile range, as appropriate. Categorical variables are reported as number and percentage. Continuous variables were compared using the Wilcoxon signed-rank test. Within-subject comparisons were made across repeated observations without correction for multiple comparisons using Friedman's test for the overall analysis and the Mann-Whitney U test for comparison of 2 groups. The relative change in biomarkers was calculated as a percentage of the 
Results
Clinical and procedural characteristics of all patients (13 men; 8 women; mean [SD] age, 59.0 [13.29] years) as well as enrolled in the study are shown in Table 1 and have been described previously in detail. 24, 25 All TASH procedures were performed in a single-session procedure using a single septal branch occlusion. During the procedure, the mean (SD) volume of ethanol administered was 1.77 (0.59) mL. 
Inflammatory Biomarkers
Measurement of serum CRP concentrations by the third generation CRP assay first showed a significant increase 24 hours after MI was initiated (0.9 mg/dL; IQR, 0.65-1.7 mg/dL) as compared with the median baseline concentration (<0.3 mg/dL; IQR, <0.3-1.05 mg/dL; P<0.001; Figure 1A ). Measurement of serum CRP concentrations by the hs assay revealed a significant increase 8 hours after induction of MI, with a continuous rise at 24 hours (2.68 mg/L; IQR, 1.23-11.8 mg/L) as compared with the median baseline concentration (2.17 mg/L; IQR, 1.15-5.06 mg/L; P=0.002; Figure 1B ). The levels of CRP as measured by the third generation and hs assays increased in every patient during the first 24 hours. In the control group, CRP concentrations showed no significant difference during the prespecified time points after coronary angiography as compared with median baseline concentration (1.8 mg/dL; IQR, 0.58-3.1 mg/dL at 24 hours versus 1.2 mg/dL; IQR, 0.53-2.2 mg/dL at baseline; P=0.10; Online Figure IA) .
All patients showed IL-6 concentrations below the 95th percentile at baseline. IL-6 concentrations increased significantly 45 minutes after induction of MI (2.59 pg/mL; IQR, 1.69-5.0 pg/mL) as compared with the median baseline concentrations (1.5 pg/mL; IQR, 1.5-2.21 pg/mL; P=0.002). We observed an increase of IL-6 concentrations in every patient during the first 2 hours with a continuous rise at all prespecified time points ( Figure 1C ). In the control group, IL-6 concentrations showed a significant difference at the first prespecified time point after coronary angiography as compared with median baseline concentration (3.08 pg/mL; IQR, 2.1-4.47 pg/mL at 120 minutes versus 2.63 pg/mL; IQR, <1.5-3.84 pg/mL at baseline; P=0.003; Online Figure IB) . We further compared the slope of the increase of CRP and IL-6 between the TASH group and the control group. The increase of CRP concentrations (P=0.026) and the increase of IL-6 concentration (P<0.001) had a steeper slope and the concentrations were significantly higher in the TASH group compared with that of the control group (Online Figure IIA and IIB) . When comparing median percentage changes versus baseline for CRP and IL-6, the relative maximum increase observed during the first 24 hours Figure IIIA and IIIB). The median serum sCD40L concentration first showed a significant change 60 minutes after initiation of myocardial infarction: 801.6 pg/mL, IQR 675.0 to 1653.5 pg/mL versus the median baseline concentration of 1750.0 pg/mL, IQR 1151.0 to 2783.0 pg/mL (P=0.016; Figure 1D ). sCD40L concentrations remained decreased until ≥24 hours after induction of myocardial infarction. All patients had a significantly lower sCD40L concentration compared with the baseline concentration after 60 minutes.
No sex-specific differences in the rates of increase were observed for the biomarkers analyzed. There was also no correlation between smoking and diabetes mellitus and the biomarker kinetics. The IL-6, CRP, hs-CRP, and sCD40L concentrations at each of the different time points are shown in Table 2 . The IL-6 and CRP concentrations in the control group at prespecified time points are shown in Online Table I . Figure 2C ). In the control group, no significant changes in granulocyte and monocyte subset counts were observed during the time course as compared with median baseline cell counts. The absolute cell counts of granulocyte and monocyte subsets at each of the different time points are shown in Online Tables II and III .
Peripheral Blood Leukocyte Subsets
High-Sensitivity Cardiac Troponin T
The release kinetics of cardiac troponin T (cTnT) as measured by a hs assay (Roche hs assay) in this patient cohort were published recently. 24 In brief, all patients showed a significant increase in hs-cTnT concentrations 15 The biomarker values of patients undergoing TASH, scaled as a percentge change (with the maximum values set to 100%) at the prespecified time points, are displayed in Figure 3 . In 
Discussion
Various prognostic biomarkers have been identified that predict poor outcome in the setting of acute coronary syndrome. 6, [27] [28] [29] [30] Inflammatory markers such as CRP reflect the extent of myocardial necrosis and correlate with cardiac outcomes after AMI. 31 CRP, mainly synthesized and secreted by hepatocytes, has been described to increase 6 hours after an acute stimulus. 32 Recent studies demonstrated that CRP predicts the loss of left ventricular ejection fraction and infarct size measured by magnet resonance imaging 3 months after AMI.
2 CRP has been the most widely studied inflammatory marker, but other biomarkers such as lipoprotein-associated phospholipase A2, myeloperoxidase, IL-6, sCD40 ligand, and pregnancy-associated plasma protein A have also shown promising results. 2, 3, 7, 8, 27, [33] [34] [35] [36] In spite of these findings, however, less is known about the exact release kinetics of inflammatory biomarkers in patients with AMI.
The present study is the first to precisely describe the early release of IL-6 and CRP, measured with conventional and hs assays, as well as the kinetics of circulating leukocyte subsets in patients undergoing TASH.
In this study, the TASH procedure was assumed to be a valuable model of human AMI because of its associated welldefined chronological biomarker release after the induction of infarction. 24, 25 One of the most important findings of our study is that blood levels of the inflammatory cytokine IL-6 and the signaling product CRP increased throughout the prespecified time points. Our study clearly shows that CRP release, as assessed by the hs assay, can be measured within 4 to 8 hours after MI and remains increased until 24 hours. The hs assay outperforms the third generation assay by virtue of its earlier detection of the first significant increase in CRP values (8 versus 24 hours).
Several pathophysiological mechanisms trigger the secretion of IL-6, including exhaustive exercise and emotional excitement. 12, 37 Previous studies demonstrated the induction of local and systemic inflammatory reactions with production of IL-6 as early as 6 hours after musculoskeletal surgical trauma. 38 In addition, IL-6 shows a distinctive circadian biphasic variation, with concentrations peaking at 4:00 pm and 4:00 am.
11 Furthermore, experimental studies have shown that short periods of myocardial ischemia followed by reperfusion trigger proinflammatory reactions with the production of cytokines such as IL-6. 9 Studies have shown that IL-6 may be of additional diagnostic value in the risk assessment of enzymenegative patients with precordial chest pain of recent onset. 3 Irrespective of higher concentrations of IL-6 in patients with left ventricular outflow tract obstruction, which indicates active proinflammatory processes, 39 our data clearly show that IL-6 is released quickly, within the first minutes after the induction of myocardial infarction, and increases during all prespecified time points. Although there was an increase in IL-6 levels at several time points in the control group, we demonstrated that the increase in patients after induction of myocardial infarction was clearly steeper and significantly greater.
Reports in the literature concerning the diagnostic accuracy of sCD40L in patients with AMI have been controversial. [4] [5] [6] 40, 41 Previous studies reported that this peptide is elevated in patients with AMI. 4, 5 Furthermore, sCD40L was shown to be elevated in patients with hypertrophic obstructive cardiomyopathy compared with healthy volunteers. 39 In contrast, we observed decreased sCD40L concentrations at the prespecified time points in the present study. We speculate that a reduction in the left ventricular outflow tract gradient and improvement in patient hemodynamics affect platelet activation, which is different from the situation with plaqueruptured AMI.
The TASH model provides a unique opportunity to compare the release kinetics of different biomarkers after AMI.
We were able to demonstrate a highly significant correlation between the maximum concentrations of hs-cTnT, which reflect the extent of myocardial necrosis, and the inflammatory markers CRP and IL-6.
We further present for the first time the exact time-course kinetics of systemic myeloid leukocyte response after MI. Whereas previous studies have already described an early, sequential mobilization and systemic release of the main myeloid subsets in a mouse model of coronary artery ligation, no study thus far has reported the earliest shifts of granulocyte and monocyte subsets in the onset of human AMI. Neutrophil blood counts have been shown previously to be an independent predictor of short-and long-term mortality after AMI. 42, 43 Neutrophilia is also suggested to serve as a potential additive diagnostic biomarker for AMI in emergency patients. 44 Our results clearly demonstrate a rapid occurrence of neutrophilia within the first hour after induction of ischemia. Estimating the precise early kinetics of bone marrow polymorphonuclear neutrophil release may further help to elucidate clinical significance and diagnostic value of neutrophil count in AMI.
Based on the animal models of MI, monocyte subsets have been assumed to orchestrate not only the initiation and resolution of cardiac inflammation but also of healing processes after MI. 45 In particular, persistently elevated levels of CD14 ++ CD16 − , classical monocytes, have been associated with the impairment of myocardial salvage and adverse left ventricular remodeling in patients after AMI. 46 Here, we show a detailed time course of CD14
++
CD16
− monocytosis within 24 hours after induction of ischemia. The isolated increase of classical monocytes after ischemia could be explained by ≥2 phenomena. First, rapid mobilization of splenic reservoirs of classical monocytes in the course of AMI is largely angiotensin II dependent. 47 Furthermore, the early release of several chemoattractant cytokines, including monocyte chemoattractant protein 1, induces monocyte migration in vitro and plays a critical role in mononuclear cell trafficking to sites of sterile inflammation. 48 Classical monocytes express high levels of CC-chemokine receptor 2, and they exit the bone marrow in a CC-chemokine receptor 2-dependent manner and are recruited in the myocardium through CC-chemokine receptor 2/monocyte chemoattractant protein-1 interactions. 49 We think that this is the first study that precisely describes release kinetics of CRP, IL-6, and circulating leukocyte subsets in patients with hypertrophic obstructive cardiomyopathy undergoing TASH. Understanding the time frame of the increase of these inflammatory markers in correlation with patient symptoms, ECG information, and imaging studies is important for individual risk stratification and individualized therapy in patients with suspected AMI.
There are some limitations of our study, however, that must be considered. The patients studied were without significant coronary artery disease and therefore without the possible phenomenon of inflammatory preconditioning, which may influence the effect of plaque rupture-related CRP release. The important role of inflammatory processes in plaque stability supports the possible benefits of lifestyle modification and drug therapy with statins and antioxidants. 50 This may prevent vulnerable plaque rupture. Furthermore, the kinetics of CRP and IL-6 release as well as the time course of leukocyte subsets after alcohol ablation might be different from the release by the stuttering thrombotic occlusion of an epicardial coronary artery where the vessel dynamically opens and closes during the early period of MI. Nevertheless, our data clearly demonstrate a significant increase in hs-CRP at 8 hours, IL-6 at 45 minutes, and polymorphonuclear neutrophils at 2 hours with a continuous rise during all prespecified time points after induction of myocardial infarction.
In conclusion, our study presents the precise kinetics of the systemic myeloid leukocyte response after MI. The data also clearly demonstrate the early release of IL-6 within the first hour after induction of MI. These results provide valuable additional evidence of the diagnostic value of inflammatory biomarkers in the setting of AMI. 
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